Analysts at Barclays initiated coverage on shares of PRA Health Sciences (NASDAQ:PRAH) in a report issued on Monday. The firm set an “overweight” rating on the medical research company’s stock.
A number of other research firms have also recently weighed in on PRAH. Mizuho set a $87.00 price target on shares of PRA Health Sciences and gave the stock a “buy” rating in a research note on Friday, December 1st. SunTrust Banks reaffirmed a “buy” rating and set a $101.00 price target on shares of PRA Health Sciences in a research note on Friday, October 27th. Credit Suisse Group reaffirmed an “outperform” rating and set a $90.00 price target (up from $84.00) on shares of PRA Health Sciences in a research note on Monday, October 16th. KeyCorp reaffirmed a “buy” rating and set a $93.00 price target (up from $86.00) on shares of PRA Health Sciences in a research note on Monday, October 30th. Finally, Robert W. Baird set a $94.00 price target on shares of PRA Health Sciences and gave the stock a “buy” rating in a research note on Friday, December 1st. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $89.09.
PRA Health Sciences (NASDAQ PRAH) opened at $82.71 on Monday. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.01 and a current ratio of 1.01. PRA Health Sciences has a 12 month low of $53.47 and a 12 month high of $84.38. The firm has a market cap of $5,241.31, a price-to-earnings ratio of 30.41, a PEG ratio of 1.43 and a beta of 0.40.
PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.03. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The business had revenue of $494.55 million for the quarter, compared to analysts’ expectations of $477.89 million. During the same period in the prior year, the company posted $0.64 EPS. The business’s revenue for the quarter was up 23.7% on a year-over-year basis. research analysts predict that PRA Health Sciences will post 3.2 earnings per share for the current year.
In related news, Director Matthew P. Young sold 5,115 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $79.90, for a total value of $408,688.50. The transaction was disclosed in a document filed with the SEC, which is available through this link. 2.10% of the stock is owned by insiders.
Several institutional investors have recently added to or reduced their stakes in PRAH. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of PRA Health Sciences by 12.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after buying an additional 160 shares in the last quarter. Carroll Financial Associates Inc. lifted its holdings in PRA Health Sciences by 127.4% in the 3rd quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock valued at $112,000 after purchasing an additional 790 shares in the last quarter. Comerica Bank purchased a new position in PRA Health Sciences in the 3rd quarter valued at about $214,000. Trustmark National Bank Trust Department purchased a new position in PRA Health Sciences in the 2nd quarter valued at about $225,000. Finally, Aperio Group LLC purchased a new position in PRA Health Sciences in the 2nd quarter valued at about $233,000. Institutional investors and hedge funds own 98.49% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “PRA Health Sciences (PRAH) Now Covered by Analysts at Barclays” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/11/pra-health-sciences-prah-now-covered-by-analysts-at-barclays.html.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.